Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution